FIELD: chemistry.
SUBSTANCE: invention relates to a solid form of 2-(imidazol-4-yl)ethanamide of pentanedioic acid, containing a zwitterion, of formula (II), characterized by a monoclinic crystal lattice structure and crystal cell edge values (in angstroms, Å): 5.39 ± 0.50 Å, 10.08 ± 0.50 Å and 19.85 ± 0.50 Å and angle value (in degrees) 100.26 ± 5.00. Solid form of 2-(imidazol-4-yl)ethanamide of pentanedioic acid of formula (II) is obtained by reacting histamine with glutaric anhydride and treating the obtained product with a mineral acid with subsequent alkalization or addition of a base until precipitation of a solid form of 2-(imidazol-4-yl)ethanamide of 1,5-pentanedioic acid, containing 2-(imidazol-4-yl)ethanamide of 1,5-pentanedioic acid in the form of zwitterion of formula (II). Invention relates to a pharmaceutical composition for treating or preventing diseases caused by viral infections, containing solid form 2-(imidazol-4-yl)ethanamide of pentanedioic acid, containing a zwitterion of formula (II), and at least one pharmaceutically acceptable excipient, wherein viral infections are parainfluenza virus, influenza virus, including influenza A, B, C and D, coronavirus.
EFFECT: solid form of 2-(imidazol-4-yl)ethanamide of pentanedioic acid, containing zwitterion, of formula (II), is used to treat or prevent diseases caused by viral infections, wherein viral infections are parainfluenza virus, influenza virus, including influenza A, B, C and D, coronavirus.
14 cl, 14 dwg, 5 tbl, 13 ex
